rituximab,ibrutinib,Bendamustine
biogen,roche,novartis,janssen,abbvie
['shine']
shine: br+ibr vs. br+placebo in pts 65yo w untreated #mcl
1 outcome pfs: sig prolongation with ibr -6.7yrs vs. placebo-4.4yrs
cr and os: no sig diff
gr 3/4 tox: 81.5% (ibr), 77.3% (placebo) median f/u:7yrs #asco22 #lysm 
Hematology and Oncology Fellow @MDAndersonNews
Interest in hematological malignancies | Tweets/opinions are mine ? medical advice.